Strong year for drug discovery

2023 was a strong year for drug discovery. Mullard et al. (2024) report:

The FDA’s Center for Drug Evaluation and Research (CDER) approved 55 new drugs in 2023, as the small molecule and biologic pharmacopoeia continues to grow. This cohort is nearly 50% bigger than the new approval class of 2022, which fell below the approval trend line. The 10-year rolling average for new CDER approvals now stands at 46 per year, the highest it has been in over 20 years. The nadir was 2010, when this average bottomed out at 25 per year.

The full list of approvals can be found here.

Originally posted at Healthcare Economist.